Immune System Diseases

69 treatments and conditions followed through the public trial records. Not medical advice. How a status is set

Lists the pairs whose condition is this category or one beneath it. A category is not a diagnosis and not advice.

Narrower: Anaphylaxis 5, Antiphospholipid Syndrome 1, Autoimmune Diseases 4, Egg Hypersensitivity 2, Food Hypersensitivity 27, Graft vs Host Disease 19, Hypersensitivity 34, Immune Complex Diseases 1, Immunoglobulin G4-Related Disease 1, Immunologic Deficiency Syndromes 11, Milk Hypersensitivity 2, Nut Hypersensitivity 2, Peanut Hypersensitivity 17, Primary Immunodeficiency Diseases 4, X-Linked Combined Immunodeficiency Diseases 2

Treatments and conditions

Immune System Diseases
Treatment and conditionWhere it standsTrials
"Rush" regimen for anaphylaxisPhase 2 trial, as of 19 Nov 2026 (not yet checked by a person)1
"Rush" regimen for egg hypersensitivityPhase 2 trial, as of 19 Nov 2026 (not yet checked by a person)1
"Rush" regimen for milk hypersensitivityPhase 2 trial, as of 19 Nov 2026 (not yet checked by a person)1
Abatacept for graft vs host diseasePhase 2 trial, as of 19 Nov 2026 (not yet checked by a person)1
allogeneic hematopoietic stem cell transplantation + FLUDARABINE PHOSPHATE + Cyclophosphamide + Mycophenolate Mofetil + Busulfan + Tacrolimus for graft vs host diseasePhase 2 trial, as of 19 Nov 2026 (not yet checked by a person)1
Alpha-galactosylceramide for graft vs host diseasePhase 2 trial, as of 19 Nov 2026 (not yet checked by a person)1
AR101 for peanut hypersensitivityPhase 3 trial, as of 19 Nov 2026 (not yet checked by a person)1
AR101 powder provided in capsules & sachets for peanut hypersensitivityPhase 3 trial, as of 19 Nov 2026 (not yet checked by a person)1
ATIR101 + T-cell depleted HSCT from a related, haploidentical donor for graft vs host diseaseTrials ended early, as of 19 Nov 2026 (not yet checked by a person)1
Base-edited hematopoietic stem and progenitor cells + ALEMTUZUMAB + Busulfan + FILGRASTIM + PALIFERMIN + PLERIXAFOR for x-linked combined immunodeficiency diseasesPhase 1 trial, as of 19 Nov 2026 (not yet checked by a person)1
Belimumab+SOC for antiphospholipid syndromePhase 2 trial, as of 19 Nov 2026 (not yet checked by a person)1
Bezuclastinib for immune complex diseasesPhase 2 trial, as of 19 Nov 2026 (not yet checked by a person)1
Biospecimen Collection + Nasal Swab + Survey Administration + REMDESIVIR for autoimmune diseasesPhase 2 trial, as of 19 Nov 2026 (not yet checked by a person)1
Corticosteroids + Ruxolitinib for graft vs host diseasePhase 2 trial, as of 19 Nov 2026 (not yet checked by a person)1
cow's milk for food hypersensitivityTrial registered, as of 19 Nov 2026 (not yet checked by a person)1
Cyclophosphamide for graft vs host diseasePhase 3 trial, as of 19 Nov 2026 (not yet checked by a person)4
Dapagliflozin for graft vs host diseasePhase 2 trial, as of 19 Nov 2026 (not yet checked by a person)1
DBFC with 150g of Alpha-gal Knock Out (KO) pork + DBFC with 150g of Wild Type (WT) pork for food hypersensitivityPhase 2 trial, as of 19 Nov 2026 (not yet checked by a person)1
Decidual Stromal Cells for graft vs host diseasePhase 2 trial, as of 19 Nov 2026 (not yet checked by a person)1
Direct intravenous injection of ivlv-X1 lentiviral vector for x-linked combined immunodeficiency diseasesTrial registered, as of 19 Nov 2026 (not yet checked by a person)1
Efgartigimod alfa for immunoglobulin g4-related diseasePhase 2 trial, as of 19 Nov 2026 (not yet checked by a person)1
Fecal microbiota for peanut hypersensitivityPhase 1 trial, as of 19 Nov 2026 (not yet checked by a person)1
fetal MSCs combined with 4SCAR T cells for autoimmune diseasesTrial registered, as of 19 Nov 2026 (not yet checked by a person)1
FMXIN002 double dose + FMXIN002 double dose + NAC + FMXIN002 single dose + FMXIN002 single dose + NAC + Epinephrine for anaphylaxisPhase 1 trial, as of 19 Nov 2026 (not yet checked by a person)1
Food allergy desensitization / Oral Immunotherapy for egg hypersensitivityTrial registered, as of 19 Nov 2026 (not yet checked by a person)1
Food allergy desensitization / Oral Immunotherapy for milk hypersensitivityTrial registered, as of 19 Nov 2026 (not yet checked by a person)1
Food allergy desensitization / Oral Immunotherapy for peanut hypersensitivityTrial registered, as of 19 Nov 2026 (not yet checked by a person)1
GVHD prophylaxis regimen + RIC regimen for immune system diseasesPhase 1 trial, as of 19 Nov 2026 (not yet checked by a person)1
Haploidentical Hematopoietic Cell Transplantation for primary immunodeficiency diseasesPhase 2 trial, as of 19 Nov 2026 (not yet checked by a person)1
Hematopoietic Stem Cell Transplantation + Total Body Irradiation + Cyclophosphamide + Mycophenolate Mofetil + Busulfan + FLUDARABINE + Tacrolimus for graft vs host diseasePhase 2 trial, as of 19 Nov 2026 (not yet checked by a person)1
Hematopoietic Stem Cell Transplantation + Total Body Irradiation + Cyclophosphamide + Mycophenolate Mofetil + Tacrolimus for graft vs host diseasePhase 2 trial, as of 19 Nov 2026 (not yet checked by a person)1
High dose of peanuts for peanut hypersensitivityTrial registered, as of 19 Nov 2026 (not yet checked by a person)1
High dose OIT for peanut hypersensitivityTrial registered, as of 19 Nov 2026 (not yet checked by a person)1
INP20 for peanut hypersensitivityPhase 1 trial, as of 19 Nov 2026 (not yet checked by a person)1
Multi-Allergen Oral Immunotherapy + Omalizumab for peanut hypersensitivityPhase 3 trial, as of 19 Nov 2026 (not yet checked by a person)1
Nut oral desensitization for nut hypersensitivityTrial registered, as of 19 Nov 2026 (not yet checked by a person)1
Omalizumab for anaphylaxisTrials ended early, as of 19 Nov 2026 (not yet checked by a person)1
Omalizumab for food hypersensitivityTrials ended early, as of 19 Nov 2026 (not yet checked by a person)1
Omalizumab for peanut hypersensitivityPhase 3 trial, as of 19 Nov 2026 (not yet checked by a person)1
Oral immunotheraphy (OIT) for nut hypersensitivityTrial registered, as of 19 Nov 2026 (not yet checked by a person)1
Oral immunotheraphy (OIT) for peanut hypersensitivityTrial registered, as of 19 Nov 2026 (not yet checked by a person)1
Oral immunotherapy with peanut for peanut hypersensitivityTrial registered, as of 19 Nov 2026 (not yet checked by a person)1
Paxlovid 10 days for immunologic deficiency syndromesPhase 2 trial, as of 19 Nov 2026 (not yet checked by a person)2
Paxlovid 10 days + REMDESIVIR for immunologic deficiency syndromesPhase 2 trial, as of 19 Nov 2026 (not yet checked by a person)1
Paxlovid 5 days for immunologic deficiency syndromesPhase 2 trial, as of 19 Nov 2026 (not yet checked by a person)2
Paxlovid 5 days + REMDESIVIR for immunologic deficiency syndromesPhase 2 trial, as of 19 Nov 2026 (not yet checked by a person)1
Peanut for anaphylaxisPhase 1 trial, as of 19 Nov 2026 (not yet checked by a person)1
Peanut for peanut hypersensitivityPhase 1 trial, as of 19 Nov 2026 (not yet checked by a person)3
Peanut in common foods or supermarket-sourced cow's milk (CM) for peanut hypersensitivityTrial registered, as of 19 Nov 2026 (not yet checked by a person)1
Peanut oral immunotherapy for anaphylaxisTrial registered, as of 19 Nov 2026 (not yet checked by a person)1
Peanut oral immunotherapy for peanut hypersensitivityPhase 2 trial, as of 19 Nov 2026 (not yet checked by a person)2
peanut powder for food hypersensitivityTrial registered, as of 19 Nov 2026 (not yet checked by a person)1
Peripheral Blood Hematopoietic Cell Transplantation (HCT) + Total body irradiation (TBI) + Cyclophosphamide + Busulfan + FLUDARABINE + FILGRASTIM + Mycophenolate Mofetil Hydrochloride + Sirolimus for graft vs host diseasePhase 1 trial, as of 19 Nov 2026 (not yet checked by a person)1
Peripheral Blood Stem Cell Transplantation + Hematopoietic Cell Transplantation + Laboratory Biomarker Analysis + Quality-of-Life Assessment + FLUDARABINE PHOSPHATE + Cyclophosphamide + Mycophenolate Mofetil + Busulfan + Tacrolimus for graft vs host diseasePhase 2 trial, as of 19 Nov 2026 (not yet checked by a person)1
Phase 1 Dose Level 1 + Phase 1 Dose Level 2 + Phase 1 Dose Level 3 for immunologic deficiency syndromesPhase 1 trial, as of 19 Nov 2026 (not yet checked by a person)1
Phase 2 Established Dose from prior study, NCT03810196 for immunologic deficiency syndromesPhase 1 trial, as of 19 Nov 2026 (not yet checked by a person)1
Phase 2 Maximum Tolerated Dose determined in Phase 1 for immunologic deficiency syndromesPhase 1 trial, as of 19 Nov 2026 (not yet checked by a person)1
Placebo for Multi-Allergen Oral Immunotherapy + Omalizumab for peanut hypersensitivityPhase 3 trial, as of 19 Nov 2026 (not yet checked by a person)1
Probiotic for hypersensitivityPhase 2 trial, as of 19 Nov 2026 (not yet checked by a person)1
Purified peanut protein extract for peanut hypersensitivityPhase 3 trial, as of 19 Nov 2026 (not yet checked by a person)3
Purified peanut protein extract + peanut for peanut hypersensitivityPhase 2 trial, as of 19 Nov 2026 (not yet checked by a person)1
reduced-dose PTCy for graft vs host diseasePhase 3 trial, as of 19 Nov 2026 (not yet checked by a person)1
Remestemcel-l for graft vs host diseaseTrial registered, as of 19 Nov 2026 (not yet checked by a person)1
Rivogenlecleucel + rimiducid for primary immunodeficiency diseasesTrial registered, as of 19 Nov 2026 (not yet checked by a person)1
Rovadicitinib for graft vs host diseasePhase 3 trial, as of 19 Nov 2026 (not yet checked by a person)1
Ruxolitinib for graft vs host diseasePhase 2 trial, as of 19 Nov 2026 (not yet checked by a person)1
Subconjuntival injection of expanded allogenic adult adipose tissue-derived mesenchymal stem cells (ASC for graft vs host diseaseTrial registered, as of 19 Nov 2026 (not yet checked by a person)1
Total Body Irradiation 12 Gy + Total Body Irradiation 8 Gy for graft vs host diseasePhase 2 trial, as of 19 Nov 2026 (not yet checked by a person)1
αβ T-cells depletion + Cyclophosphamide for graft vs host diseasePhase 2 trial, as of 19 Nov 2026 (not yet checked by a person)1

Categories are from Medical Subject Headings (MeSH), U.S. National Library of Medicine, courtesy of the U.S. National Library of Medicine: MeSH. They may not reflect the most current data available from NLM. NLM does not endorse this site.